In this webinar, we will present key insights from preliminary findings by the TUFTS Center for the Study of Drug Development, exploring how a comprehensive model that brings CDMO and CRO services under one roof can significantly impact the expected Net Present Value (eNPV) of drug development programs. We will demonstrate how streamlined services across drug substance, drug product, and clinical research can enhance efficiency, reduce timelines, and ultimately deliver high-quality therapies to patients faster.
Key takeaways include:
- The financial and operational benefits of leveraging eNPV modeling for combined CDMO and CRO services.
- Practical strategies for simplifying the development journey with Thermo Fisher Scientific’s Accelerator™ Drug Development.
- Case studies showcasing real-world successes of biotech and biopharma companies in accelerating their path from lab to patient.
